M.D.C. Holdings, Inc. (NYSE:MDC) Expected to Post Earnings of $1.37 Per Share


Share on StockTwits

Analysts predict that M.D.C. Holdings, Inc. (NYSE:MDC) will report earnings of $1.37 per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for M.D.C.’s earnings. The lowest EPS estimate is $1.31 and the highest is $1.46. M.D.C. posted earnings per share of $0.52 in the same quarter last year, which suggests a positive year-over-year growth rate of 163.5%. The business is expected to issue its next earnings results before the market opens on Thursday, April 29th.

On average, analysts expect that M.D.C. will report full-year earnings of $6.96 per share for the current year, with EPS estimates ranging from $6.41 to $7.60. For the next financial year, analysts forecast that the business will report earnings of $7.45 per share, with EPS estimates ranging from $6.59 to $8.38. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover M.D.C..

M.D.C. (NYSE:MDC) last issued its quarterly earnings results on Tuesday, February 2nd. The construction company reported $2.19 earnings per share for the quarter, topping the consensus estimate of $1.73 by $0.46. M.D.C. had a return on equity of 16.78% and a net margin of 8.27%. The business had revenue of $1.18 billion during the quarter, compared to the consensus estimate of $1.21 billion. During the same quarter last year, the company earned $1.42 earnings per share. The company’s quarterly revenue was up 9.9% on a year-over-year basis.

A number of equities research analysts recently commented on MDC shares. Wolfe Research started coverage on M.D.C. in a report on Monday, March 22nd. They set a “peer perform” rating for the company. Raymond James lifted their target price on M.D.C. from $61.00 to $71.00 and gave the stock a “strong-buy” rating in a report on Monday, January 25th. Finally, Bank of America reiterated an “underperform” rating and set a $63.00 price target on shares of M.D.C. in a research report on Thursday, March 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $58.50.

Shares of M.D.C. stock traded down $0.57 on Thursday, reaching $59.42. 16,499 shares of the stock were exchanged, compared to its average volume of 652,613. The company has a quick ratio of 1.89, a current ratio of 7.69 and a debt-to-equity ratio of 0.59. M.D.C. has a twelve month low of $20.38 and a twelve month high of $61.81. The firm has a market capitalization of $3.87 billion, a price-to-earnings ratio of 12.41, a PEG ratio of 0.48 and a beta of 1.53. The business has a 50 day moving average price of $57.39 and a two-hundred day moving average price of $51.43.

The business also recently declared a quarterly dividend, which was paid on Wednesday, February 24th. Investors of record on Wednesday, February 10th were given a dividend of $0.3429 per share. This represents a $1.37 annualized dividend and a yield of 2.31%. The ex-dividend date was Tuesday, February 9th. M.D.C.’s dividend payout ratio is currently 39.78%.

In other news, Chairman Larry A. Mizel sold 125,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 10th. The stock was sold at an average price of $59.31, for a total value of $7,413,750.00. Following the completion of the sale, the chairman now directly owns 254,343 shares in the company, valued at $15,085,083.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Leslie B. Fox sold 4,200 shares of the business’s stock in a transaction that occurred on Monday, March 8th. The shares were sold at an average price of $56.21, for a total value of $236,082.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 157,406 shares of company stock valued at $9,243,404. 25.20% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of MDC. CVentures Inc. purchased a new stake in shares of M.D.C. in the fourth quarter valued at approximately $390,649,000. BlackRock Inc. boosted its stake in shares of M.D.C. by 8.7% in the fourth quarter. BlackRock Inc. now owns 9,988,492 shares of the construction company’s stock worth $485,443,000 after acquiring an additional 800,254 shares during the last quarter. Norges Bank acquired a new stake in shares of M.D.C. in the fourth quarter worth approximately $30,642,000. Vision Capital Corp boosted its stake in shares of M.D.C. by 482.4% in the fourth quarter. Vision Capital Corp now owns 466,479 shares of the construction company’s stock worth $22,671,000 after acquiring an additional 386,377 shares during the last quarter. Finally, Peregrine Capital Management LLC boosted its stake in shares of M.D.C. by 81.0% in the fourth quarter. Peregrine Capital Management LLC now owns 356,574 shares of the construction company’s stock worth $17,329,000 after acquiring an additional 159,583 shares during the last quarter. Institutional investors and hedge funds own 73.61% of the company’s stock.

About M.D.C.

M.DC Holdings, Inc, through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name.

Further Reading: Learning About the VIX – Volatility Index

Get a free copy of the Zacks research report on M.D.C. (MDC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for M.D.C. (NYSE:MDC)

Receive News & Ratings for M.D.C. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for M.D.C. and related companies with MarketBeat.com's FREE daily email newsletter.